- Cat. No.
- A11755
PF 4708671
PF 4708671 is a highly specific inhibitor of p70 ribosomal S6 kinase (S6K1) that inhibits S6K1-mediated phosphorylation of S6 protein in response to IGF-1 , while having no effect on highly related RSK and MSK kinases.
Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
RSK inhibitors act on p90 ribosomal S6 kinases (RSKs), four effectors of growth factor signaling. Extracellular signal-regulated kinases 1 and 2 (ERK1, ERK2) activate RSK1 to RSK4 at the end of the mitogen-activated protein kinase (MAPK) cascade. Each RSK has two kinase domains, and the C-terminal domain switches on the N-terminal domain that phosphorylates substrates. RSK substrates regulate transcription, protein synthesis, cell survival and cell motility. BI-D1870 and LJH685 occupy the ATP site of the N-terminal domain in all four isoforms. FMK targets the C-terminal domain, and SL 0101-1 is a flavonoid glycoside that inhibits RSK1 and RSK2. PF 4708671 and LY-2584702 instead inhibit the related p70 S6 kinase 1 (S6K1).
PF 4708671 is a highly specific inhibitor of p70 ribosomal S6 kinase (S6K1) that inhibits S6K1-mediated phosphorylation of S6 protein in response to IGF-1 , while having no effect on highly related RSK and MSK kinases.
SL 0101-1 is a selective inhibitor of p90 ribosomal S6 kinase (RSK) (IC50 = 89 nM for RSK2). It also inhibits the growth of MCF-7 human breast cancer cells with no effect on the normal breast cell line.
FMK is potent, highly specific and irreversible inhibitor of p90 ribosomal protein S6 kinase RSK1 and RSK2; Fmk binds in the CTKD ATP-binding site and inhibits RSK autophosphorylation at Ser386. Fmk induces significant apoptosis in human FGFR3-expressing, t(4;14)-positive multiple myeloma cells.
BI-D1870 is a potent and specific inhibitor of the p90 ribosomal S6 kinase (RSK) isoforms in vitro and in vivo, which inhibits RSK1, RSK2, RSK3 and RSK4 in vitro with an IC50 of 10–30 nM.
Synonyms: LYS6K2
LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.
AT7867 is a novel and potent inhibitor of both AKT and the downstream kinase p70 S6 kinase (p70S6K) and also of protein kinase A.
CMK is a RSK2 kinase inhibitor which exhibits similar potency but less chemical stability compared with FMK.
AT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors.
BIX 02565 is a novel inhibitor of ribosomal S6 kinase 2 with IC50 value of 1 nM.
LJH685 is a potent , specific and selective RSK inhibitor, inhibits RSK1, 2, and 3 biochemical activities with IC50 of 4 to 13 nM.
Synonyms: LJI-30
LJI308 is a new and potent pan-RSK inhibitor, with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
Synonyms: AT-7867 dihydrochloride
AT7867 dihydrochloride is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively, little activity outside the AGC kinase family.
LY-2584702 tosylate salt is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.
Synonyms: Salicylic acid sodium salt; 2-Hydroxybenzoic acid sodium salt
Sodium Salicylate (Salicylic acid sodium salt) inhibits cyclo-oxygenase-2 (COX-2) activity independently of transcription factor (NF-κB) activation. Sodium Salicylate is also a S6K inhibitor.Sodium Salicylate is a NF-κB inhibitor that decreases inflammatory gene expression and improves repair in aged muscle.
AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.
Synonyms: LY2584702
LY-2584702 hydrochloride is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
Synonyms: S6K1-IN-1
S6K-18 is a highly selective inhibitor of ribosomal protein S6 kinase beta-1 (S6K1, p70S6K, p70-S6K).
TAS0612 is an orally active inhibitor of RSK, AKT, and S6K, targeting key signaling pathways involved in cell proliferation and survival. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Its application extends to studies investigating the mechanisms of tumor growth and resistance to therapy.
RSK-IN-2 is a potent inhibitor of the RSK family of kinases, demonstrating IC50 values of 37.89 nM for RSK2, 30.78 nM for RSK1, 20.51 nM for RSK3, and 91.28 nM for RSK4. This compound effectively inhibits tumor cell proliferation, induces apoptosis, and enforces cell cycle arrest at the G2/M phase. RSK-IN-2 is relevant for research in cancer biology and therapeutic development targeting RSK pathways.
RSK-IN-1 is a selective inhibitor of the RSK (ribosomal protein S6 kinase) signaling pathway. It effectively inhibits the phosphorylation of YB-1, a key regulator in oncogenic processes. This compound demonstrates significant anti-tumor activity, making it valuable for research focused on cancer biology and therapeutic interventions targeting RSK pathway dysregulation.
RSK4-IN-2 is a selective inhibitor of RSK4 with a potent inhibitory effect, demonstrating an IC50 of 17 nM. This compound effectively suppresses cell growth and invasion in esophageal squamous cell carcinoma (ESCC) by inhibiting the phosphorylation of RSK4 downstream targets. Additionally, RSK4-IN-2 has shown significant activity in reducing tumor growth and metastasis in ESCC mouse models, making it a valuable tool for research into ESCC development and progression.
Out of stock
All 3 sizes
BRD7389 is a specific inhibitor of the RSK family kinases, demonstrating IC50 values of 1.5 μM for RSK1, 2.4 μM for RSK2, and 1.2 μM for RSK3. This small-molecule compound effectively induces insulin expression in pancreatic α-cells, making it a valuable tool for research into diabetes and related metabolic disorders. Its selective action on RSK kinases allows for detailed exploration of their roles in cellular signaling pathways.
RSK4-IN-1 is a potent inhibitor of the RSK4 kinase, exhibiting an IC50 value of 9.5 nM. This compound demonstrates significant antitumor activity, making it a valuable tool for research focused on cancer biology and therapeutic interventions. RSK4-IN-1 is ideal for studying the pathways regulated by RSK4 and their implications in tumor progression and treatment resistance.
S6K1-IN-DG2 is a potent inhibitor of p70S6K, exhibiting an IC50 of less than 100 nM. This compound specifically targets the p70S6K pathway, which plays a critical role in regulating cell growth, proliferation, and metabolism. S6K1-IN-DG2 is valuable for research applications focused on studying the effects of p70S6K inhibition in cancer biology and metabolic disorders.
FMK-MEA is a potent and selective inhibitor of p90 Ribosomal S6 Kinase (RSK). It effectively disrupts RSK signaling pathways, which are critical in regulating cell growth, survival, and differentiation. This compound is valuable for research applications exploring the role of RSK in cancer, neurobiology, and other cellular processes where RSK-mediated signaling is implicated.